FIELD: biotechnology.
SUBSTANCE: monoclonal antibody that binds to IL17A is proposed. The present invention also discloses a nucleic acid encoding said antibody, an expression vector and a host cell containing the sequence of said nucleic acid, and a method for producing the antibody. In addition, the invention is related to an antibody-drug conjugate, pharmaceutical composition and kit, which are used for treatment of psoriasis.
EFFECT: said monoclonal antibody specifically binds IL17A protein with high affinity, has superior or equivalent ability to block IL17A and IL17A/F-induced inflammatory cytokine secretion by human HFF epidermal fibroblasts compared to comparable drugs, and has improved in vivo efficacy.
22 cl, 9 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| RGMa BINDING PROTEIN AND ITS USE | 2016 |
|
RU2809500C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| METHOD AND COMPOSITION FOR TREATING CANCER, DESTROYING METASTATIC CANCER CELLS AND PREVENTING METASTASES OF CANCER, USING ANTIBODIES TO END PRODUCTS OF INCREASED GLYCATION (AGE) | 2017 |
|
RU2728964C2 |
| EphA4 ANTIBODY | 2020 |
|
RU2816371C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| METHOD OF PURIFICATION FOR REMOVING TYROSINE SULPHATED ANTIBODIES VARIANTS, PURIFIED COMPOSITIONS | 2017 |
|
RU2793400C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
